🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Elanco stock downgraded as pipeline outlook dims - Morgan Stanley

EditorEmilio Ghigini
Published 09/19/2024, 04:30 AM
ELAN
-


On Thursday, Morgan Stanley adjusted its stance on Elanco Animal Health (NYSE:ELAN), downgrading the company's stock from Overweight to Equalweight and lowering the price target to $15 from $17.

The firm's assessment acknowledges Elanco's upcoming innovative products such as Zenrelia, Credelio Quattro, and Bovaer, expected in 2024, and IL-31, potentially in 2025. These innovations are anticipated to guide Elanco towards a more favorable trajectory.

The reevaluation of Elanco's stock comes amid considerations that the near-term contributions of these products are already reflected in market expectations. There are concerns regarding the challenges these products may face, including competition in the dermatology and parasiticides segments from rivals with line extensions and further market saturation.

Morgan Stanley's original Overweight rating was based on a turnaround story fueled by Elanco's innovation pipeline projected for 2024 and 2025. However, the firm has decided to adopt a more cautious approach due to the lack of clear evidence on the speed and scale of market uptake for Elanco's new products. This conservative outlook is also influenced by potential difficulties with product launches, especially highlighted by the setbacks with Zenrelia.

The revised price target of $15 represents a shift in Morgan Stanley's expectations, factoring in the potential risks and uncertainties surrounding Elanco's future product launches. The decision to downgrade reflects a more neutral view of the company's stock performance in the face of these anticipated challenges.

In other recent news, Elanco Animal Health Incorporated has been navigating a challenging situation with its contract manufacturing partner, TriRx Speke Ltd. Despite this, Elanco anticipates minimal supply disruptions for the year 2024 and maintains its full-year adjusted EBITDA guidance of between $900 million and $940 million.

In parallel, Elanco is nearing the final stages of the FDA approval process for its new veterinary medicine, Credelio Quattro. The company's innovation sales are projected to reach between $600 million and $700 million in 2025.

Elanco has also secured a new $350 million credit facility, aiming to manage its debt and ensure financial flexibility. The funds from this facility will be used to repay outstanding obligations under a previous loan and for general corporate purposes. The company has not disclosed any further details regarding specific initiatives or investments that will be supported by this new line of credit.

Elanco's financial performance for the second quarter of 2024 exceeded expectations with significant revenue, adjusted EBITDA, and adjusted EPS growth. The company is preparing for the launches of Zenrelia and Credelio Quattro, targeting the global canine dermatology and parasiticide markets.

Elanco maintains its full-year outlook, projecting organic constant currency revenue growth of 3% to 4%. These recent developments demonstrate Elanco's commitment to financial stability, strategic growth, and sustainability.


InvestingPro Insights


As Morgan Stanley recalibrates its position on Elanco Animal Health (NYSE:ELAN), it's essential to consider the latest financial metrics and analyst insights to understand the company's current standing. Elanco's market capitalization stands at $7.24 billion, and while the company has faced profitability challenges over the last twelve months, analysts predict a return to profitability this year. This optimism is underpinned by a revenue growth of 3.89% in the last twelve months as of Q2 2024, indicating a steady upward trajectory in sales.

InvestingPro Tips highlight that Elanco's liquid assets surpass its short-term obligations, providing a cushion for operational needs. Despite trading at a high EBIT valuation multiple, the company's price to book ratio is relatively modest at 1.22, suggesting that the stock might be reasonably valued in terms of its net asset value.

For investors seeking a deeper analysis, InvestingPro offers additional insights, including a fair value estimate of $15.07, closely aligned with Morgan Stanley's revised price target. The platform also notes the absence of dividend payments, which may influence investment decisions for income-focused shareholders. To explore further, investors can find a total of 6 additional InvestingPro Tips for Elanco at https://www.investing.com/pro/ELAN.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.